Healthcare entity
Weiss Ratings is the most frequent co-covered peer, appearing in 5 of the 8 tracked stories. market-trends accounts for 6 of the 8 tracked stories, while 2 other categories carry the remainder. Negative sentiment reaches 0% here, compared with 26% across the 836-story beat baseline for the same window.
Last mentioned: 1d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Weiss Ratings is the most frequent co-covered peer, appearing in 5 of the 8 tracked stories. market-trends accounts for 6 of the 8 tracked stories, while 2 other categories carry the remainder. Negative sentiment reaches 0% here, compared with 26% across the 836-story beat baseline for the same window. Their average consequence score of 5 runs below the beat's 6 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window. That works out to roughly 0.4 stories per week across a 157-day span. The busiest single day carried 2. Wall Street Zen appears in 8 tracked Healthcare stories published from March 10, 2026 through August 13, 2026.
Computed from the 8 stories linked to this entity, with beat comparisons drawn from all 836 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Wall Street Zen. Shared-story counts are live from our verified record — not editorial picks.
Q2 2026 Earnings Release
Company reported EPS of ($0.19), missing consensus by $0.03.
Ladenburg Thalmann Upgrade
Ladenburg Thalmann upgraded CRVS to ‘strong-buy’.
Weiss Ratings Upgrade
Weiss Ratings upgraded Corvus from ‘sell (e+)’ to ‘sell (d-)’.
Director Insider Purchase
Director David Scott Moore acquired 21,700 shares at $11.53 per share, totaling $250,201.
Wall Street Zen Downgrade
Wall Street Zen downgraded CRVS from ‘hold’ to ‘sell’.
Goldman Sachs Initiates Coverage
Goldman Sachs issued a ‘buy’ rating and a $40.00 target price for Corvus Pharmaceuticals.
Insider Selling
President and another insider report share sales in regulatory filings.
Analyst Downgrade
Wall Street Zen cuts ALHC rating to Hold.
Offering Priced
Secondary offering is priced at $19.46 per share.
Secondary Offering Announced
Company announces intent to sell 13.2 million shares to raise capital.
Q4 Earnings Report
Alignment Healthcare reports a declining net loss for the fourth quarter of 2025.
For healthcare and medical device stakeholders, Apyx Medical's Q1 revenue of $12.49 million beat consensus by $1.96 million, yet the stock fell 1.8% to $4.38. The decline on 60% below-average volume suggests limited conviction, while analysts maintain a moderate buy rating and $6.50 target. The company's strong liquidity ratios contrast with its negative net margin and return on equity.
Ensysce Biosciences short interest soared 619.9% to 364,278 shares as its stock trades at $0.30, while Focus Universal posted just $0.05M in quarterly revenue. The data highlights severe financial fragility across two small healthcare and device innovators.
Corvus Pharmaceuticals missed Q2 EPS by $0.03, highlighting the financial fragility of early-stage oncology R&D. With no near-term data readouts, the miss draws attention to cash burn and the critical need for clinical progress to justify its $1.17B valuation.
Source: dailypolitical.com · tickerreport.com
Collegium Pharmaceutical's Q2 2026 earnings beat signals sustained demand for its abuse-deterrent pain medications. Revenue grew 6.3% to $199.88M, and EPS of $1.92 surpassed forecasts by $0.20, indicating commercial strength despite regulatory pressures.
Teva Pharmaceutical's FY2026 EPS guidance fell short of the $2.17 consensus, while revenue projections of $16.5-$16.9B matched expectations. For healthcare leaders, the miss underscores ongoing generic drug pricing pressures and the importance of a diversified pipeline.
Wall Street Zen downgraded vaccine maker Novavax to sell, raising alarms in the healthcare sector. The stock traded at $7.41, far below its $13 consensus target, with a negative P/E of -12.78.
Alignment Healthcare (NASDAQ: ALHC) has reported significant insider selling, including a 29,113-share disposal by its President, shortly after a major secondary offering. These transactions occur as the company navigates a shift in analyst sentiment and a challenging regulatory environment for Medicare Advantage providers.
Source: tickerreport.com · themarketsdaily.com
Wall Street Zen has lowered its rating on Alignment Healthcare (ALHC) to "Hold," reflecting broader caution within the Medicare Advantage sector. The downgrade comes as specialized insurers face tightening margins and regulatory shifts in the federal reimbursement landscape.
Source: themarketsdaily.com · themarketsdaily.com
Wall Street Zen is linked from 8 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
